Payment overview · 2025
General Payments
$331.97
20 reported records · 7 companies
Healthcare provider profile · identity verified
Molly Bailey Brown, FNP
Allopathic & Osteopathic Physicians|Preventive Medicine|Occupational Medicine · BILOXI, MS · NPI 1033464508
Verified facts
What the public records show
CMS Open Payments records show Molly Bailey Brown, FNP received $331.97 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.87 | 35.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.20 | 24.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.30 | 20.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.23 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.36 | 5.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.00 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.01 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.97 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $116.87 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.87 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.35 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 71 |
| Lisinopril | Lisinopril | 202 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 47 |
| Metformin Hcl | Metformin Hcl | 153 | 46 |
| Buspirone Hcl | Buspirone Hcl | 130 | 31 |
| Losartan Potassium | Losartan Potassium | 120 | 41 |
| Furosemide | Furosemide | 108 | 43 |
| Potassium Chloride | Potassium Chloride | 107 | 34 |
| Omeprazole | Omeprazole | 103 | 27 |
| Gabapentin | Gabapentin | 99 | 31 |
| Trazodone Hcl | Trazodone Hcl | 99 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 35 |
| Simvastatin | Simvastatin | 96 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 30 |
| Mounjaro | Tirzepatide | 80 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 24 |
| Meloxicam | Meloxicam | 76 | 27 |
| Metformin Hcl Er | Metformin Hcl | 75 | 22 |
| Carvedilol | Carvedilol | 73 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 15 |
| Allopurinol | Allopurinol | 65 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 25 |
| Sertraline Hcl | Sertraline Hcl | 65 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 23 |
| Ozempic | Semaglutide | 61 | 13 |
| Ezetimibe | Ezetimibe | 58 | 13 |
| Glimepiride | Glimepiride | 57 | 15 |
| Trulicity | Dulaglutide | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Famotidine | Famotidine | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Jardiance | Empagliflozin | 42 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 20 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 29 |
| Ibuprofen | Ibuprofen | 38 | 12 |
| Montelukast Sodium | Montelukast Sodium | 38 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 19 |
| Valsartan | Valsartan | 38 | 12 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 13 |
| Amoxicillin | Amoxicillin | 29 | 24 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.97 · 20 records | Lilly USA, LLC | AIRSUPRA, CAPLYTA, CONTRAVE, Cologuard Collection Kit, FARXIGA, MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error